Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Harvard Business School
Johnson and Johnson
Merck
Medtronic

Last Updated: September 30, 2022

UPNEEQ Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Upneeq, and when can generic versions of Upneeq launch?

Upneeq is a drug marketed by Rvl Pharms and is included in one NDA. There are ten patents protecting this drug.

This drug has forty-three patent family members in twenty-six countries.

The generic ingredient in UPNEEQ is oxymetazoline hydrochloride. There are three drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the oxymetazoline hydrochloride profile page.

DrugPatentWatch® Generic Entry Outlook for Upneeq

Indicators of Generic Entry

< Available with Subscription >

  Sign up for a Free Trial

US Patents and Regulatory Information for UPNEEQ

UPNEEQ is protected by ten US patents and one FDA Regulatory Exclusivity.

Patents protecting UPNEEQ

Compositions and methods for treating ocular disorders
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING BLEPHAROPTOSIS

Oxymetazoline compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Oxymetazoline compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Compositions and methods for non-surgical treatment of ptosis
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING BLEPHAROPTOSIS

Compositions and methods for treating ocular disorders
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING BLEPHAROPTOSIS


Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Oxymetazoline compositions
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Compositions and methods for treating ocular disorders
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING BLEPHAROPTOSIS

Compositions and methods for non-surgical treatment of ptosis
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING BLEPHAROPTOSIS

Compositions and methods for non-surgical treatment of Ptosis
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF TREATING BLEPHAROPTOSIS

FDA Regulatory Exclusivity protecting UPNEEQ

NEW PRODUCT
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Rvl Pharms UPNEEQ oxymetazoline hydrochloride SOLUTION/DROPS;OPHTHALMIC 212520-001 Jul 8, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Rvl Pharms UPNEEQ oxymetazoline hydrochloride SOLUTION/DROPS;OPHTHALMIC 212520-001 Jul 8, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Rvl Pharms UPNEEQ oxymetazoline hydrochloride SOLUTION/DROPS;OPHTHALMIC 212520-001 Jul 8, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Rvl Pharms UPNEEQ oxymetazoline hydrochloride SOLUTION/DROPS;OPHTHALMIC 212520-001 Jul 8, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Rvl Pharms UPNEEQ oxymetazoline hydrochloride SOLUTION/DROPS;OPHTHALMIC 212520-001 Jul 8, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
Rvl Pharms UPNEEQ oxymetazoline hydrochloride SOLUTION/DROPS;OPHTHALMIC 212520-001 Jul 8, 2020 RX Yes Yes See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for UPNEEQ

When does loss-of-exclusivity occur for UPNEEQ?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 20268329
Estimated Expiration: See Plans and Pricing

Brazil

Patent: 2021022404
Estimated Expiration: See Plans and Pricing

Canada

Patent: 39443
Estimated Expiration: See Plans and Pricing

China

Patent: 1888326
Estimated Expiration: See Plans and Pricing

Colombia

Patent: 21015265
Estimated Expiration: See Plans and Pricing

European Patent Office

Patent: 65737
Estimated Expiration: See Plans and Pricing

Israel

Patent: 7831
Estimated Expiration: See Plans and Pricing

Japan

Patent: 20183373
Estimated Expiration: See Plans and Pricing

Patent: 21191802
Estimated Expiration: See Plans and Pricing

Morocco

Patent: 895
Estimated Expiration: See Plans and Pricing

Peru

Patent: 220384
Estimated Expiration: See Plans and Pricing

Singapore

Patent: 202112272T
Estimated Expiration: See Plans and Pricing

South Korea

Patent: 2410503
Estimated Expiration: See Plans and Pricing

Patent: 200128629
Estimated Expiration: See Plans and Pricing

Patent: 220084264
Estimated Expiration: See Plans and Pricing

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering UPNEEQ around the world.

Country Patent Number Title Estimated Expiration
Morocco 55895 COMPOSITIONS D'OXYMÉTAZOLINE ET PROCÉDÉS DE TRAITEMENT DE TROUBLES OCULAIRES See Plans and Pricing
Peru 20220384 COMPOSICIONES Y METODOS DE OXIMETAZOLINA PARA EL TRATAMIENTO DE TRASTORNOS OCULARES See Plans and Pricing
Japan 2020183373 眼疾患を処置するためのオキシメタゾリン組成物および方法 (OXYMETAZOLINE COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DISEASES) See Plans and Pricing
Hungary E046740 See Plans and Pricing
Slovenia 2680829 See Plans and Pricing
Japan 2021191802 眼疾患を処置するためのオキシメタゾリン組成物および方法 (OXYMETAZOLINE COMPOSITIONS AND METHODS FOR TREATING OPHTHALMIC DISEASES) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
Mallinckrodt
Express Scripts
McKesson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.